



PRESS RELEASE

Update to the corporate events calendar

Capua (CE), 3 November 2017 – Following the communications to the market by Pierrel S.p.A. (“**Pierrel**” or the “**Company**”) on 26 January 2017, 4 April 2017, 27 April 2017, 30 May 2017, 1 June 2017, 30 June 2017, 14 July 2017, 7 August 2017, 9 August 2017, 15 September 2017, 27 September 2017 and 6 October 2017 (available on the Company’s website at www.pierrelgroup.com, section Press/Press Release), also pursuant to Article 2.6.2 of the Regulations of Borsa Italiana S.p.A, Pierrel S.p.A. discloses that the meeting of Pierrel’s Board of Directors for the approval on a voluntary basis of the interim report of the Pierrel Group at 30 September 2017 will be held on 7 November 2017.

* * *

Pierrel S.p.A. specialises in the manufacture of pharmaceutical specialty products (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

The Pierrel Group is listed on the MTA exchange organised and managed by Borsa Italiana, and has over 60 years’ experience in the pharmaceutical sector, as one of Europe’s leading producers of local and dental anaesthetics.

Pierrel owns a production unit in Capua, near Naples, Italy, which has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines.

The subsidiary Pierrel Pharma S.r.l. with sole shareholder has registered and distributes the Orabloc® dental anaesthetic in Canada, the US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy

For further information:

Pierrel S.p.A.

Investor Relations

Fulvio Citaredo

E-mail: investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

Global Consult S.r.l.

Media Relations

Rossana Del Forno

E-mail: areacomunicazione@globalconsultsrl.com

tel. +39 333 6178665